A phase I/II, multicenter study evaluating the feasibility, safety, and efficacy of point-of-care manufactured GLPG5101 (19CP02) in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r NHL) (CP0201-NHL)

Study title: 
A phase I/II, multicenter study evaluating the feasibility, safety, and efficacy of point-of-care manufactured GLPG5101 (19CP02) in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r NHL) (CP0201-NHL)
Long title: 
A phase I/II, multicenter study evaluating the feasibility, safety, and efficacy of point-of-care manufactured GLPG5101 (19CP02) in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r NHL) (CP0201-NHL)
Date receipt dossier: 
18 Jan 2024
EudraCT number: 
2023-503830-27
Pharmaceutical study code: 
GLPG5101 (19CP02)
Company / Sponsor: 
Galapagos NV
Phase: 
I/II
Treated organism: 
Humans
Indication category: 
Cancer therapy
Disease: 
relapsed/refractory B-cell non-Hodgkin lymphoma (r/r NHL)
Therapeutic approach: 
Immunotherapy
Genetic modification: 
BCMA CAR
Method of transfer of nucleic acid of interest: 
Lentiviral vector
Administered biological material: 
Autologous T cells transduced with lentiviral vectors expressing BCMA-CAR
Route of administration: 
Intravenous
Locations in Belgium: 
UZ Leuven
Type of procedure: 
Contained use only
Current status: 
Authorized